Navigation Links
ULURU Inc. Reports Third Quarter 2010 Financial Results
Date:11/15/2010

ADDISON, Texas, Nov. 15, 2010 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) today announced its financial results for the third quarter ended September 30, 2010.

For the third quarter of 2010, the Company reported a net loss of $1.2 million, or $0.01 per share, compared with a net loss of $1.5 million, or $0.02 per share, for the same period last year.  For the nine months ended September 30, 2010, the Company reported a net loss of $4.7 million, or $0.06 per share, compared with a net loss of $7.5 million, or $0.11 per share, for the same period last year.  At September 30, 2010, the Company held cash and cash equivalents of $1.3 million, compared with $1.9 million at December 31, 2009.

Commenting on the financial results Kerry P. Gray, President and CEO, stated, "Financial performance is substantially in line with our plan for the quarter.  Revenues from U.S. Altrazeal® sales were below forecasted levels primarily due to a reduction in wholesaler inventory levels, reflecting our ability to supply product immediately on receipt of an order, and reduced hospital patient visits which have returned to normal levels in October.  We continue to closely control our expenses and prioritize our investments to those projects which are expected to yield the highest returns."

Mr. Gray continued, "Substantial progress has been made on many fronts in the third quarter, including:

  • Execution of a worldwide animal health distribution agreement;
  • Realigning our sales and marketing activities to focus on diabetic foot ulcers, venous ulcers, and geriatric wounds where we have excellent clinical evidence supporting cost effective treatment with Altrazeal®;
  • Advancing the product pipeline, including working to resolve issues with our silver product, planning a clinical study with our collagen product, and fina
    '/>"/>

  • SOURCE ULURU Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
    2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
    3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
    4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
    5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
    6. ULURU Inc. Reports Second Quarter 2010 Financial Results
    7. ULURU Inc. Announces Conference Call
    8. ULURU Inc. Provides Altrazeal® Clinical Update
    9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    10. Spherix Reports Second Quarter Earnings
    11. Tapestry Reports Second Quarter 2007 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/16/2014)... 2014  DNAtrix, Inc., experts in oncolytic virus ... treated with the company,s lead product, DNX-2401, a ... randomized, multicenter, open-label Phase Ib study for patients ... with leading neurosurgeons and neuro-oncologists in the US, ... randomized Phase Ib study of DNX-2401 at Moffitt ...
    (Date:9/16/2014)... 16, 2014  Eli Lilly and Company (NYSE: ... an agreement to co-develop and commercialize AZD3293, an ... in development as a potential treatment for Alzheimer,s ... is characterized by the accumulation of amyloid plaque ... with the development of beta-amyloid. Inhibiting BACE is ...
    (Date:9/15/2014)... Sept. 16, 2014  Bayer HealthCare and Orion ... Finland , have begun to enroll ... an investigational oral androgen receptor inhibitor in clinical ... men with castration-resistant prostate cancer who have rising ... metastases. The trial is designed to determine the ...
    Breaking Medicine Technology:DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
    ... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that ... at the Lazard Capital Markets 8th Annual Healthcare Conference, being ... Bentsur,s presentation is scheduled to take place on Wednesday, November ... audio webcast of Mr. Bentsur,s presentation will be accessible from ...
    ... 2011 Booth # 407 at The American ... NxStage® Medical, Inc. (Nasdaq: NXTM ), ... announced that its Medisystems division has won a ... Solution to Atlantic Dialysis Management Services centers. ...
    Cached Medicine Technology:Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 3
    (Date:9/16/2014)... 2014) The Columbia University College of Dental ... Excellence in Diversity (HEED) award from INSIGHT Into ... in higher education. As a recipient of the ... and universities that demonstrate an outstanding commitment to ... 82 other recipients in INSIGHT Into Diversity magazine,s ...
    (Date:9/16/2014)... 2014. Kessler Foundation researchers have published a study ... the executive deficits found in individuals with multiple ... for executive deficits in multiple sclerosis? Evidence from ... ahead of print on August 18 by ... Victoria Leavitt, PhD, of the Manhattan Memory Center, ...
    (Date:9/16/2014)... some of Australia,s best fast bowlers, track and field ... thanks to a new training technique discovered by a ... of Health and Biomedical Innovation, with support from the ... Sport Science Research, has studied the run-ups of elite ... jump and pole vault and found the vertical objects ...
    (Date:9/16/2014)... September 15, 2014 For patients with locally advanced ... ablative radiation (SABR) may be a promising treatment ... may not otherwise be an option, according to ... Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. , Surgery ... with pancreatic ductal adenocarcinoma (PDA), the most common ...
    (Date:9/16/2014)... abstracts to be presented at the ESMO 2014 Congress ... at 12:00 (CEST) to give you a first glimpse ... oncology Congress, under the leading theme Precision Medicine in ... genuinely targeted therapy is now possible for an increasing ... all working towards a common goal --improved patient outcomes. ...
    Breaking Medicine News(10 mins):Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Getting the jump on competitors: QUT study 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:ESMO 2014 Congress Preview 2
    ... According to a research it was found that radiotherapy given ... against breast cancer//. The researchers from UK and US said ... the recurrence of cancer when compared to the conventional regime ... of the 10-year trial which was funded by the Cancer ...
    ... with stimulant medications rather than nonstimulant medications or ... such as mixed amphetamine salts (MAS) and methylphenidates ... medications such as modafinil. ,This conclusion is ... representing the past 25 years of research involving ...
    ... mobilisation against the disease in the last five years, frustrating ... UN says in advance of a review conference. ,A ... are scheduled to meet Wednesday-Friday at UN headquarters to assess ... General Assembly to try to reverse the epidemic by 2010. ...
    ... of genetically caused diseases from type 1 diabetes to alopecia, ... system, autoimmune disease can be understood//. ,By age ... infection of the skin and/or mucous membrane and adrenal gland ... in the Aire gene) and nearly about 16 autoimmune diseases ...
    ... were suffered, was caused by distinctly personal habits and ... do but to suffer in silence. Others like constipation, ... limiting some of their day-to-day activities. ,Researches ... modification instead of taking variety of drugs. ...
    ... statistics regarding the use of tobacco amongst teenagers, which has ... tobacco and its products. , ,These figures were made ... World No Tobacco Day; on May 31st. This years theme ... or disguise,'' conveying cigarette smoking in any form is extremely ...
    Cached Medicine News:Health News:Stimulant Medications More Effective In Treating ADHD Than Nonstimulants 2Health News:Global War Against AIDS May Fail Target, Warns UN 2Health News:Autoimmune Diseases – Newer Preventive Measure 2Health News:Autoimmune Diseases – Newer Preventive Measure 3Health News:Silence Puts Comfort For Digestive Syndrome 2
    ... Innovations' Instrument Manager (IM) is an instrument ... system that enables laboratories to work more ... as a data management solution that stands ... information system, filling those important gaps in ...
    ... These color vision tests have been designed ... the type and estimating the grade of ... measure Red, Green, Blue, Yellow. They provide ... deficiencies. Screening is accomplished using the initial ...
    ... sets are designed to indicate color deficiency ... is used to separate Medium and Strong ... test is much more difficult and is ... Both of these tests provide basic ...
    Single Use Loading Units with Titanium Staplers for use with MULTIFIRE ENDO TA™ 30 12 mm (Single Use Staplers with Titanium Staplers)....
    Medicine Products: